孕早期最大滋养层厚度联合母血及尿液生物标志物无创产前诊断先天性巨细胞病毒感染
该回顾性队列纳入127例孕早期母体CMV原发感染孕妇,于11+0至14+6周用三维超声测量最大滋养层厚度(MTT),并结合母血CMV-PCR及母体生物标志物。羊水CMV-PCR阳性者MTT中位数显著高于阴性者(21.3 mm vs 17.1 mm,P=0.017)。MTT联合母血CMV-PCR阳性及伐更昔洛韦启动延迟至10周后,预测羊水CMV-PCR阳性的AUC为0.94,敏感度80.00%,特异度93.26%。
要点
- 孕早期三维超声测量的最大滋养层厚度(MTT)增高与CMV垂直传播相关,可能作为早期无创标志物。
- MTT预测垂直传播的最佳阈值为19.0 mm,敏感度83.33%(95%CI 62.25-100%)。
- MTT联合母血CMV-PCR阳性及伐更昔洛韦启动延迟至10周后,预测羊水CMV-PCR阳性的AUC达0.94。
核心结论
- 孕早期三维超声测量的MTT增高与CMV垂直传播相关,可能作为早期无创标志物;联合母血CMV-PCR状态及治疗启动时机可提高预测准确性,并可能指导早期咨询与针对性侵入性检查。
研究设计与样本
- 回顾性队列研究,纳入2019年10月至2024年5月转诊至Necker-Enfants malades医院的127例孕早期CMV母体原发感染孕妇,排除多胎妊娠及胎儿遗传异常。
关键影像表现/征象
- 羊水CMV-PCR阳性者MTT中位数为21.3 mm,阴性者为17.1 mm,阳性者显著更高(P=0.017)。
- MTT测量观察者间ICC为0.827(95%CI 0.763-0.875),重复性良好。
诊断标准与关键数值
- MTT预测垂直传播的最佳阈值为19.0 mm,敏感度83.33%(95%CI 62.25-100%)。
- MTT联合孕早期母血CMV-PCR阳性及伐更昔洛韦启动延迟至10周后,预测羊水CMV-PCR阳性的AUC为0.94(95%CI 0.87-0.99)。
- 上述联合模型预测羊水CMV-PCR阳性的敏感度80.00%(95%CI 44.39-97.48%),特异度93.26%(95%CI 85.90-97.49%),阳性预测值57.14%(95%CI 36.71-75.40%),阴性预测值97.65%(95%CI 92.31-99.31%)。
- 垂直传播经绒毛膜绒毛和/或羊水CMV-PCR确认;绒毛膜绒毛CMV-PCR阳性率7.1%(采样中位孕周13.7周),羊水CMV-PCR阳性率9.4%(采样中位孕周17.4周)。
临床应用与阅片要点
- 孕早期三维超声测量MTT可作为CMV垂直传播的早期无创预测指标,联合母血CMV-PCR及治疗启动时机有助于指导早期咨询与针对性侵入性检查。
- 120例(94.5%)孕妇接受伐更昔洛韦二级预防;伐更昔洛韦启动延迟至10周后为联合预测模型中的变量之一。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Congenital cytomegalovirus (CMV) infection, a leading cause of sensorineural hearing loss and neurological impairment, is typically diagnosed by second-trimester amniocentesis, delaying clinical decision-making. This study aimed to assess the predictive value of maximum trophoblast thickness (MTT) measured by first-trimester three-dimensional (3D) ultrasound, in combination with maternal biomarkers, for the early prediction of CMV vertical transmission.
METHODS: This was a retrospective cohort study of pregnant women, not previously seropositive for CMV, who were referred to Necker-Enfants malades Hospital between October 2019 and May 2024 for maternal primary infection (MPI) with CMV in early pregnancy. Multiple pregnancies and fetuses with genetic anomaly were excluded. MTT measurement was performed using 3D multiplanar ultrasound between 11 + 0 and 14 + 6 weeks' gestation by two independent observers. Interobserver agreement for MTT measurement was assessed using the intraclass correlation coefficient (ICC). We recorded maternal characteristics, including first-trimester maternal biomarkers (pregnancy-associated plasma protein-A, free β-human chorionic gonadotropin and placental growth factor) and CMV polymerase chain reaction (PCR) status in the maternal blood and urine. Vertical transmission was confirmed by CMV-PCR in chorionic villi (CV) and/or amniotic fluid (AF). The predictive value of MTT, alone and in combination with relevant covariables, was assessed using logistic regression models and receiver-operating-characteristics (ROC)-curve analysis.
RESULTS: A total of 127 pregnant women with a median gestational age (GA) at CMV-MPI of 2.0 (interquartile range, -2.5 to 7.0) weeks were included, of whom 120 (94.5%) received valacyclovir for secondary prevention. CMV-PCR was positive in 7.1% of CV samples (median GA at sampling, 13.7 weeks) and 9.4% of AF samples (median GA at sampling, 17.4 weeks). MTT was significantly higher in cases with a positive CMV-PCR result in AF compared to those with a negative result (median, 21.3 mm vs 17.1 mm; P = 0.017). The ICC for MTT measurement was 0.827 (95% CI, 0.763-0.875), indicating good interobserver reproducibility. ROC-curve analysis identified 19.0 mm as the optimal MTT threshold, yielding a sensitivity of 83.33% (95% CI, 62.25-100%) for predicting vertical transmission. When combined with CMV-PCR positivity in the maternal blood in the first trimester and delayed valacyclovir initiation beyond 10 weeks, the predictive model achieved an area under the ROC curve of 0.94 (95% CI, 0.87-0.99) for CMV-PCR positivity in AF, with a sensitivity of 80.00% (95% CI, 44.39-97.48%), specificity of 93.26% (95% CI, 85.90-97.49%), positive predictive value of 57.14% (95% CI, 36.71-75.40%) and negative predictive value of 97.65% (95% CI, 92.31-99.31%).
CONCLUSION: Increased MTT measured by 3D ultrasound in the first trimester is associated with CMV vertical transmission and may serve as an early non-invasive marker. Combining MTT with CMV-PCR status in the maternal blood and timing at initiation of treatment improves predictive accuracy and could guide early counseling and targeted invasive testing. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bourgon N, Fernandez M, Chatzakis C, et al. Non-invasive prenatal diagnosis of congenital cytomegalovirus infection using maximum trophoblast thickness and biomarkers in maternal blood and urine in first trimester. Ultrasound Obstet Gynecol. 2025. PMID: 41047886. doi:10.1002/uog.70019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。